Peptide record

TPDB02273

Tyroserleutide Anticancer Antioxidant Selfassembly standard
3 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB02273
Tyroserleutide
Anticancer Antioxidant Selfassembly
Cancer-related peptides Functional / health-promoting peptides Self-assembling and biomaterial peptides
AntiCP 2.0 CancerPPD 2.0 Peptipedia SATPdb dbACP iACP-DRLF AnOxPePred - 1.0 AODB Multi-AOP SAPdb
standard
No
A 3-aa standard-residue multi-activity (Anticancer, Antioxidant, and Selfassembly) peptide sequence curated from AntiCP 2.0, CancerPPD 2.0, Peptipedia, and other sources, with an available 3D structural model.
Sequence
YSL
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C18H27N3O6
ARNDCEQGHIKMFPTWV
LSY
381.43
5.94
0
0
2
-0
-0.46
0.567
130.00
Mammalian: 2.8 hour Yeast: 10 min E.coli: 2 min
1490
3.91
2
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
1
L
0
K
0
M
0
F
0
P
1
S
0
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 1 K: 0 M: 0 F: 0 P: 0 S: 1 T: 0 W: 0 Y: 1 V: 0
Chemical Descriptors
3 reviewed residue count
C18H27N3O6 sequence-only estimate (linear, free termini)
381.43 sequence-only estimate (linear, free termini)
5.94 sequence-only estimate (linear, free termini)
-0 sequence-only estimate (linear, free termini)
-0.46 sequence-only estimate (linear, free termini)
0.567 sequence-only estimate (linear, free termini)
Free Activity
L Activity
Linear Activity
Free Activity
Antitumor Activity
Synthetic Peptide Activity
Self-Assembly Information 1 records
Record 1 Selfassembly

Source

31211520
10.1016/j.compbiomed.2021.104391
SAPdb: A database of short peptides and the corresponding nanostructures formed by self-assembly

Self-Assembly

Nanostructure formation
Nanoparticle nanoparticles
pH: 7.4 solvent: uranium acetate solution concentration: 0.5% (w/v)
Selfassembly; Nanostructure=Nanoparticle; nanoparticles; Trigger=pH: 7.4; solvent: uranium acetate solution; concentration: 0.5% (w/v)
Transmission Electron Microscopy (TEM)
Selfassembly
Evidence Records 10 records
Evidence 1 Activity

Activity

49.4% cytotoxic at 0.1 µg/ml
Anticancer

Target

Skin Cancer
B16-F10
Skin

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

51.2% cytotoxic at 1 µg/ml
Anticancer

Target

Skin Cancer
B16-F10
Skin

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 3 Activity

Activity

53.0% cytotoxic at 10 µg/ml
Anticancer

Target

Skin Cancer
B16-F10
Skin

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 4 Activity

Activity

61.2% cytotoxic at 100 µg/ml
Anticancer

Target

Skin Cancer
B16-F10
Skin

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 5 Activity

Activity

39.0% cytotoxic at 0.1 µg/ml
Anticancer

Target

Liver Cancer
BEL-7402
Liver

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 6 Activity

Activity

20.8% cytotoxic at 1 µg/ml
Anticancer

Target

Liver Cancer
BEL-7402
Liver

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 7 Activity

Activity

33.8% cytotoxic at 10 µg/ml
Anticancer

Target

Liver Cancer
BEL-7402
Liver

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 8 Activity

Activity

35.6% cytotoxic at 100 µg/ml
Anticancer

Target

Liver Cancer
BEL-7402
Liver

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 9 Activity

Activity

Antioxidative activity
Antioxidant

Source & Reference

AODB
DFBP
Evidence 10 Selfassembly

Activity

Nanostructure formation
Selfassembly Nanostructure=Nanoparticle nanoparticles Trigger=pH: 7.4 solvent: uranium acetate solution concentration: 0.5% (w/v)
Nanoparticle nanoparticles

Source & Reference

SAPdb
10.1016/j.compbiomed.2021.104391

Other

None specified
pH: 7.4 solvent: uranium acetate solution concentration: 0.5% (w/v)
Transmission Electron Microscopy (TEM)
31211520
SAPdb: A database of short peptides and the corresponding nanostructures formed by self-assembly
SAPdb ID NA low-detail seed row from experimentally curated self-assembly database.
Additional Detail Fields 5 fields
pH: 7.4 solvent: uranium acetate solution concentration: 0.5% (w/v)
None specified
SAPdb ID NA low-detail seed row from experimentally curated self-assembly database.
31211520
SAPdb: A database of short peptides and the corresponding nanostructures formed by self-assembly